Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 30.7 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM MES, 100 mM NaCl, pH6.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD38, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human CD38, His Tag (Cat. No. CD8-H5224) is more than 95% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Immobilized Human CD38, His Tag (Cat. No. CD8-H5224) at 5 μg/mL (100 μL/well) can bind Anti-CD38 MAb, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Daratumumab/Hyaluronidase-fihj | Approved | Johnson & Johnson Innovative Medicine | Darzalex Faspro, Darzquro | United States | Multiple Myeloma | Janssen Biotech Inc | 2020-05-01 | Monoclonal Gammopathy of Undetermined Significance; Rejection in heart transplantation; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Amyloidosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Multiple Myeloma; Myelodysplastic Syndromes; Hodgkin Disease; Smoldering Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Peripheral Nervous System Diseases; Leukemia, Myelogenous, Chronic; Bone marrow transplant rejection | Details | |
Isatuximab | SAR-650984; hu38SB19 | Approved | Immunogen Inc | Sarclisa | United States | Multiple Myeloma | Sanofi-Aventis U.S. Llc | 2020-03-02 | Satiety Response; Carcinoma, Non-Small-Cell Lung; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Macroglossia; Leukemia, Myeloid, Acute; Nausea; Amyloidosis; Hepatomegaly; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Gastrointestinal Hemorrhage; Diarrhea; Prostatic Neoplasms; Goiter, Nodular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Hodgkin Disease; Neoplasms; Purpura; Leukemia, Plasma Cell; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Lymphadenopathy; Paraproteinemias; Hematologic Neoplasms; Constipation | Details |
Daratumumab | JNJ-54767414 | Approved | Johnson & Johnson Innovative Medicine | Darzalex, 兆珂速, 兆珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2015-11-16 | Rejection of organ transplantation; Hypersensitivity; POEMS Syndrome; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Alzheimer Disease; Urologic Neoplasms; Amyloidosis; Lymphoma, Primary Effusion; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Prostatic Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Multiple Myeloma; Carcinoma, Transitional Cell; Autoimmune Diseases; Hodgkin Disease; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Paraproteinemias; Genital Neoplasms, Male; Rejection of renal transplantation; Kidney Neoplasms | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Mezagitamab | TAK-079 | Phase 3 Clinical | Takeda | Purpura, Thrombocytopenic, Idiopathic; Hematologic Neoplasms; Myasthenia Gravis; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis | Details |
Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 3 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 2 Clinical | SinoCelltech Ltd | Hematologic Neoplasms; Glomerulonephritis, IGA; Autoimmune Diseases | Details |
Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome; Thrombocytopenia | Details | |
Erzotabart | GEN-3014 | Phase 2 Clinical | Genmab A/S | Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
CID-103 | CID-103; TSK011010 | Phase 2 Clinical | Tusk Therapeutics Ltd | Purpura, Thrombocytopenic, Idiopathic; Multiple Myeloma; Thrombocytopenia | Details |
BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | PeptiDream Inc, Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals | Multiple Myeloma | Details |
Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Hematologic Neoplasms; Glomerulonephritis, IGA; Multiple Myeloma; Lupus Erythematosus, Systemic; Anemia, Aplastic; Lymphoma; Thrombocytopenia | Details |
89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
T-007 (TNK Therapeutics/Celularity) | Phase 1 Clinical | Tnk Therapeutics Inc | Multiple Myeloma | Details | |
Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
Phase 1 Clinical | The Second Hospital Of Shandong University | Multiple Myeloma | Details | ||
SAR-444559 | SAR444559; SAR-444559 | Phase 1 Clinical | Sanofi | Inflammation | Details |
68Ga-NB-381 | 68Ga-NB381; 68Ga-NB-381; 18F-FDG(The First Affiliated Hospital Of Beijing University) | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Multiple Myeloma | Details |
CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details | |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
CD38-SADA:177 Lu-DOTA Drug Complex | Phase 1 Clinical | Y-Mabs Therapeutics Inc | Lymphoma, Non-Hodgkin | Details | |
Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | Phase 1 Clinical | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | Multiple Myeloma | Details | |
Daratumumab biosimilar (Chiatai Tianqing) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details | |
CART-38(University of Pennsylvania) | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | Details | |
GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
Daratumumab biosimilar (Henlius) | HLX-15 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Multiple Myeloma | Details |
211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
SAR-442085 | SAR-442085 | Phase 1 Clinical | Sanofi | Multiple Myeloma | Details |
KJ-C2320 | KJ-C2320 | Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.